• Explore /
  • Poster
  • / Amivantamab and lazertinib in treatment-naïve <em>EGFR-</em>mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.

Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.

Abstract Poster

Authors

null

Se-Hoon Lee

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Se-Hoon Lee , Byoung Chul Cho , Ji-Youn Han , Eun Kyung Cho , Jong-Seok Lee , Ki Hyeong Lee , Joshua C Curtin , Grace Gao , John Xie , Robert W. Schnepp , Joshua Michael Bauml , Roland E. Knoblauch , Meena Thayu , Dong-Wan Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02609776

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9134)

DOI

10.1200/JCO.2023.41.16_suppl.9134

Abstract #

9134

Poster Bd #

122

Abstract Disclosures

Similar Posters

First Author: Catherine A. Shu

First Author: Jonathan N. Priantti

First Author: Nicolas Girard

First Author: Akito Hata